Recent Updates
Recently added Catalysts

GEN1106

Phase 1

Solid Tumors | Monoclonal antibody | Oncology |Genmab A/S|Last Updated: Mar 11, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment103
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07416123A Study of GEN1106 in Participants With Solid TumorsPHASE1 RECRUITING 103 — — Mar 1, 2026Jun 1, 2029Mar 11, 2026 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
GEN1106BIOLOGICALIntravenous (IV) infusion.
Unlock Study Design Details
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT07416123studyFirstPostDate: changed